2329 A randomized phase III study of S-1 alone versus S-1 plus immunomodulator lentinan for unresectable or recurrent gastric cancer (JFMC36–0701). (September 2015) - Nishikawa, K.; Yoshino, S.; Morita, S.; Takahashi, T.; Sakata, K.; Nagao, J.; Nemoto, H.; Murakami, N.; Matsuda, T.; Hasegawa, H.; Shimizu, R.; Yoshikawa, T.; et al.